

Appendix 2 (as supplied by authors): US population estimates for overweight and obesity based on NHANES III (1988-1994) and NHANES 1999-2004.

	NHANES III (1988-1994)		NHANES 1999-2004	
	Estimated population size		Estimated population size	
	85 351 412 (4 129 005)		112 497 856 (4 191 285)	
	<i>N</i>	Percentage ^a	<i>N</i>	Percentage ^a
Total	4367	-	3600	-
Sex, male	2104	53.4 (1.1)	1884	53.0 (1.1)
Age at examination				
20 to 29 yr	675	15.0 (0.9)	499	16.1 (1.0)
30 to 39 yr	940	25.1 (1.7)	603	20.8 (0.7)
40 to 49 yr	805	21.7 (1.4)	730	24.7 (1.0)
50 to 59 yr	593	15.6 (0.8)	547	18.6 (0.9)
≥ 60 yr	1354	22.6 (1.5)	1221	19.9 (1.0)
Race/ethnicity				
Non-Hispanic white	1566	73.0 (1.8)	1625	69.3 (2.2)
Non-Hispanic black	1317	12.9 (0.8)	737	11.9 (1.3)
Mexican-American	1332	6.3 (0.6)	982	8.8 (1.3)
Other	152	7.8 (1.4)	256	10.0 (1.6)
Smoking				
Current smoker	1035	26.1 (1.1)	735	22.5 (0.9)
Former smoker	1154	28.8 (1.1)	1015	27.0 (1.1)
Never smoked	2178	45.1 (1.3)	1838	50.3 (1.4)
Unknown/refused	0	0.00 (0.00)	12	0.2 (0.1)
Body mass index				
Overweight	2526	59.6 (1.2)	1930	53.8 (1.0)
Class I obese	1180	26.2 (1.0)	993	27.2 (0.7)
Class II obese	445	9.6 (0.9)	418	11.5 (0.7)
Class III obese	216	4.6 (0.4)	259	7.5 (1.4)
EOSS stage				
0	462	11.3 (0.9)	46	1.4 (0.3)
1	1018	24.2 (1.0)	932	28.4 (1.1)
2	2365	53.0 (1.4)	2258	62.9 (1.2)
3	522	11.5 (0.9)	364	7.2 (0.6)
Hypertension, Yes ^b	1420 / 4337	29.7 (1.3)	1288 / 3568	32.0 (1.2)
Diabetes, Yes ^c	421 / 4360	6.1 (0.6)	407 / 3,551	7.9 (0.6)
Osteoarthritis, Yes	188 / 3540	6.2 (0.5)	270 / 3593	7.7 (0.4)
Aminotransferase elevation, Yes ^d	236 / 4179	5.2 (0.7)	168 / 3597	4.5 (0.5)
Metabolic syndrome, Yes ^e	2055	43.6 (0.015)	1707	44.3 (1.0)

Appendix to: Padwal RS, Pajewski N, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict all-cause mortality in a population-representative cohort of people with overweight and obesity. *CMAJ* 2011. DOI:10.1503/cmaj110387.

Hypertriglyceridemic waist, Yes ^f	1,660	38.4 (1.4)	1406 / 3593	37.9 (1.2)
Candidate for bariatric surgery, Yes ^g	546	12.3 (1.0)	560	15.6 (1.0)
Functional impairment, Yes ^h	520 / 2977	13.2 (1.1)	559 / 1647	33.4 (1.9)
ADL limitations, Yes ^h	67 / 2982	1.6 (0.3)	89 / 1651	5.3 (1.0)
	N	Mean	N	Mean
Fasting glucose (mmol/L)	4257	5.9 (0.05)	3583	5.8 (0.03)
Systolic blood pressure (mm Hg)	4367	124.81 (0.39)	3481	123.77 (0.36)
Diastolic blood pressure (mm Hg)	4363	76.34 (0.24)	3481	73.48 (0.33)
Total cholesterol (mmol/L)	4220	5.5 (0.3)	3597	5.3 (0.03)
LDL cholesterol (mmol/L)	3660	3.5 (0.02)	3254	3.2 (0.02)
HDL cholesterol (mmol/L)	4187	1.2 (0.01)	3597	1.2 (0.01)
Triglycerides (mmol/L)	4210	1.8 (0.05)	3597	1.7 (0.04)
eGFR ⁱ (mL/min/1.73m ²)	4170	97.87 (0.59)	3590	94.24 (0.61)

ADL = activities of daily living, eGFR = estimated glomerular filtration rate, EOSS = Edmonton obesity staging system, HDL = high-density lipoprotein, LDL = low-density lipoprotein.

*Population includes individuals 20 years of age or older randomized to the morning mobile examination center exam, had Body Mass Index measured, no previous cancer diagnosis (self-report), and were not currently pregnant (women).

Numbers in parentheses denote standard errors

^a Survey-weighted percentage within the sample of overweight and obese subjects (BMI \geq 25 kg/m²)

^b Based on self-report of high blood pressure/hypertension

^c Based on self-report of diabetes, insulin use, or oral diabetic agent use

^d Unexplained aminotransferase elevation was defined as elevated AST or ALT without the presence of hepatitis B surface antigen, hepatitis C antibody, transferrin saturation > 50% , daily average alcohol consumption > 2 drinks per day (men), or daily average alcohol consumption > 1 drinks per day (women).

^e Metabolic syndrome defined according to the ATP III Clinical Criteria (see Grundy et al. (2004)). See text for details.

^f Hypertriglyceridemic Waist defined as in Arsenault et al. (2010). See text for details.

^g Candidates for Bariatric Surgery were defined according to an adaptation of the criteria in Yermilov et al. (2009) based on available data in NHANES (See methods).

^h See methods for definitions of functional and ADL limitations

ⁱ Based on calibrated serum creatinine (see Methods)